Pneumonia Basic Science

A special issue of Medical Sciences (ISSN 2076-3271). This special issue belongs to the section "Pneumology and Respiratory Diseases".

Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 3673

Special Issue Editors


E-Mail Website
Guest Editor
Director Pulmonary Intensive Care Unit, Respiratory Institute, Hospital Clinic of Barcelona, Barcelona, Spain
Interests: respiratory medicine; epidemiology; risk factors; outcome; treatment; prevention and pathogenetic mechanisms of respiratory infections; community-acquired pneumonia; intensive care
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, IRCCS Fondazione Ospedale Maggiore Policlinico Cà Granda, 20122 Milan, Italy
Interests: pneumonia; COPD; bronchiectasis; cystic fibrosis; lung transplantation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pneumonia is a clinical and public health issue worldwide, affecting approximately 400 million people and causing more than 2 million deaths/year. Studies on pathophysiology are providing new insights into the mechanisms underlying the host response and have led to the discovery of new molecules designed to face infection and inflammation related to pneumonia. This Special Issue of Medical Sciences focuses on recent advances in the role of microbiome, host genetics, immune response, new biomarkers, and new treatment of this disease.

The goal is to stimulate research and clinical interests in this exciting field with the hope of developing strategies for prevention, better understanding the pathophysiological mechanisms and improving treatment outcomes both in immunocompetent and immunocompromised patients with pneumonia.

You may choose our Joint Special Issue in Biomedicines.

Dr. Antoni Torres
Prof. Dr. Francesco Blasi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medical Sciences is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pneumonia
  • microbiome
  • genetics
  • immunopathology

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

11 pages, 238 KiB  
Review
Adjuvant Inhaled Corticosteroids in Community-Acquired Pneumonia: A Review Article
by Faeq R. Kukhon and Emir Festic
Med. Sci. 2021, 9(2), 34; https://doi.org/10.3390/medsci9020034 - 23 May 2021
Viewed by 3050
Abstract
Community-acquired pneumonia is still a major cause of morbidity and mortality worldwide. Since the inflammatory response induced by the immune system is often a major contributor to the lung injury, it becomes reasonable to assess the potential benefit of anti-inflammatory agents in treating [...] Read more.
Community-acquired pneumonia is still a major cause of morbidity and mortality worldwide. Since the inflammatory response induced by the immune system is often a major contributor to the lung injury, it becomes reasonable to assess the potential benefit of anti-inflammatory agents in treating community-acquired pneumonia. The role of corticosteroids as adjunct anti-inflammatory agents in treating community-acquired pneumonia is still controversial. Several studies have assessed the benefit of their use in patients with community-acquired pneumonia. In most of those studies, the route of corticosteroids administration was systemic. The aim of this article is to provide a concise review of the role of corticosteroids in treating community-acquired pneumonia when administered via inhalational route, with the potential benefit of avoiding systemic side effects of corticosteroids while exerting the same anti-inflammatory effects on the lungs. Conclusion: the use of inhaled corticosteroids may be of benefit in certain patient subsets with community-acquired pneumonia. Further randomized controlled trials are needed for better determination of such patient subsets. Full article
(This article belongs to the Special Issue Pneumonia Basic Science)
Back to TopTop